CHEPLAPHARM Arzneimittel GmbH

Publications

This section provides relevant information as well as ongoing and timely updates on the strategic and operative success stories of our steadily growing Company.

support_agent

Your contact persons

Jens Remmers

Head of Treasury & Investor Relations

IR center of information

Financial Reports

1st December 2022
Earnings Call Q3 2022 Results
29th November 2022
Publication Quarterly Report Q3 2022
1st September 2022
Earnings Call H1 2022 Results
29th August 2022
Publication 1st Half-Year Report 2022
2nd June 2022
Investor Call Quarterly Report Q1 2022
31st May 2022
Publication Quarterly Report Q1 2022
10th May 2022
Investor Call Full Financial Year 2021 audited
29th April 2022
Publication Full Financial Year 2021 audited
30th November 2021
Investor Call Quarterly Report Q3 2021
19th November 2021
Publication Quarterly Report Q3 2021
24th August 2021
Investor Call Quarterly Report Q2 2021
20th August 2021
Publication Quarterly Report Q2 2021
Find out how you can benefit

Publications

The latest from CHEPLAPHARM

CHEPLAPHARM completes it´s largest acquisition so far

Greifswald, 01/05/2021 - CHEPLAPHARM successfully closes acquisition of cardiovascular and metabolic portfolio from Takeda

Last week CHEPLAPHARM closed it’s largest acquisition so far, in terms of purchase price and volume. The acquisition from Takeda Pharmaceutical Company Limited includes a variety of branded products, targeting the therapeutic areas of cardiology, endocrinology, sleep disorders and gastrointestinal diseases. The products will be distributed mainly in the European markets.

"This transaction demonstrates our growing visibility and reputation as a global player in the pharmaceutical market. The portfolio contains high-quality branded products that are spread across multiple therapeutic areas, thus meeting our goal of maximum diversification," explains Sebastian Braun, CEO of CHEPLAPHARM.

In 2020, Cheplapharm was able to build on the success of previous years and achieved stable growth rates in many respects. These include, in particular, the number of new products and extensive investments in conjunction with a new, solid financing structure, the successful hiring of more than 100 new employees and the extension of an adjacent building to expand our company site in Greifswald.


Investor Relations topics

Back to top expand_less